← Back to Search

N/A

Peri-capsular Nerve Group (PENG) for Postoperative Pain

Phase 4
Waitlist Available
Led By Rawad Hamzi, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up hour 24
Awards & highlights

Summary

This trial compares two methods for pain relief after hip replacement surgery. One method aims to reduce pain without causing muscle weakness, while the other can lead to muscle weakness. The goal is to find out which method helps patients recover faster.

Eligible Conditions
  • Hip Pain
  • Postoperative Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~hour 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and hour 24 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Numeric Rating Scale (NRS) Pain Score
Secondary study objectives
Distance Ambulated
Motor Strength
NRS Pain Score
+1 more

Side effects data

From 2023 Phase 4 trial • 154 Patients • NCT05261009
1%
Right hip dislocation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Peri-capsular Nerve Group (PENG)
Lumbar Plexus Block (LPB)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Peri-capsular Nerve Group (PENG)Experimental Treatment1 Intervention
Those subjects assigned to the PENG treatment arm will receive a PENG block using 20mL of 0.2% ropivacaine with 1:400,000 epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
Group II: Lumbar Plexus Block (LPB)Active Control1 Intervention
Those subjects assigned to the LPB treatment arm will receive a stimulation-based LPB dosed with 20cc of 0.2% ropivacaine with 1:400,000 dilution epinephrine dosed in 5mL increments with negative aspiration beforehand and between each aliquot.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Peri-capsular Nerve Group (PENG)
2022
Completed Phase 4
~160

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,269 Previous Clinical Trials
1,013,879 Total Patients Enrolled
4 Trials studying Postoperative Pain
246 Patients Enrolled for Postoperative Pain
Rawad Hamzi, MDPrincipal InvestigatorWake Forest University Health Sciences
1 Previous Clinical Trials
31 Total Patients Enrolled
~47 spots leftby Oct 2025